Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 8, 2009 - Issue 3
Submit an article Journal homepage
422
Views
36
CrossRef citations to date
0
Altmetric
Drug Safety Evaluations

Oseltamivir for treatment and prophylaxis of influenza infection

Patricia Schirmer Stanford University, VA Palo Alto Health Care System, Division of Infectious Diseases & Geographic Medicine, 3801 Miranda Avenue (132), Palo Alto, CA 94304, USA +1 650 852 3408; +1 650 858 3978; [email protected] or [email protected]
, MD &
Mark Holodniy Stanford University, VA Palo Alto Health Care System, Division of Infectious Diseases & Geographic Medicine, 3801 Miranda Avenue (132), Palo Alto, CA 94304, USA +1 650 852 3408; +1 650 858 3978; [email protected] or [email protected]
, MD
Pages 357-371 | Published online: 09 Apr 2009

Bibliography

  • Arabi Y, Gomersall CD, Ahmed QA, et al. The critically ill avian influenza A (H5N1) patient. Critical Care Med 2007;35(5):1397-403
  • Jones M, Del Mar C. Safety of neuraminidase inhibitors for influenza. Expert Opin Drug Saf 2006;5(5):603-8
  • Yuen KY, Wong SSY. Human infection by avian influenza A H5N1. Hong Kong Med J 2005;11(3):189-99
  • Beigel JH. Influenza. Critical Care Med 2008;36(9):2660-6
  • Available from: http://www.cdc.gov/flu/professionals/acip/background.htm
  • Available from: http://www.who.int/mediacentre/factsheets/fs211/en/
  • Gambotto A, Barratt-Boyes SM, de Jong MD, et al. Human infection with highly pathogenic H5N1 influenza virus. Lancet 2008;371(9622):1464-75
  • Abdel-Ghafar AN, Chotiptayasunondh T, Gao Z, et al. Update on avian influenza A (H5N1) virus infection in humans. N Engl J Med 2008;358(3):261-73
  • Beigel J, Bray M. Current and future antiviral therapy of severe seasonal and avian influenza. Antiviral Res 2008;78(1):91-102
  • Ison MG, Gubareva LV, Atmar RL, et al. Recovery of drug-resistant influenza virus from immunocompromised patients: a case series. J Infect Dis 2006;193(6):760-4
  • Weinstock DM, Gubareva LV, Zuccotti G. Prolonged shedding of multidrug-resistant influenza A virus in an immunocompromised patient. N Engl J Med 2003;348(9):867-8
  • Whitley RJ, Hayden FG, Reisinger KS, et al. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J 2001;20(2):127-33
  • Kiso M, Mitamura K, Sakai-Tagawa Y, et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 2004;364(9436):759-65
  • Smit M, Beynon KA, Murdoch DR, Jennings LC. Comparison of the NOW Influenza A & B, NOW Flu A, NOW Flu B, and Directigen Flu A assays, and immunofluorescence with viral culture for the detection of influenza A and B viruses. Diagn Microbiol Infect Dis 2007;57(1):67-70
  • Moscona A. Medical management of influenza infection. Ann Rev Med 2008;59:397-413
  • Moscona A. Neuraminidase inhibitors for influenza. N Engl J Med 2005;353(13):1363-73
  • Jackson D, Barclay W, Zürcher T. Characterization of recombinant influenza B viruses with key neuraminidase inhibitor resistance mutations. J Antimicrob Chemother 2005;55(2):162-9
  • Monto AS. Antivirals and influenza: frequency of resistance. Pediatr Infect Dis J 2008;27(10 Suppl):S110-2
  • Hayden F, Klimov A, Tashiro M, et al. Neuraminidase inhibitor susceptibility network position statement: antiviral resistance in influenza A/H5N1 viruses. Antiviral Ther 2005;10(8):873-7
  • Tumpey TM, GarcÃa-Sastre A, Mikulasova A, et al. Existing antivirals are effective against influenza viruses with genes from the 1918 pandemic virus. Proc Natl Acad Sci USA 2002;99(21):13849-54
  • Bright RA, Medina MJ, Xu X, et al. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 2005;366(9492):1175-81
  • Bright RA, Shay DK, Shu B, et al. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA 2006;295(8):891-4
  • Monto AS, Whitley RJ. Seasonal and pandemic influenza: a 2007 update on challenges and solutions. Clin Infect Dis 2008;46(7):1024-31
  • He G, Massarella J, Ward P. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin Pharmacokinet 1999;37(6):471-84
  • Ferraris O, Lina B. Mutations of neuraminidase implicated in neuraminidase inhibitors resistance. J Clin Virol 2008;41(1):13-9
  • von Itzstein M. The war against influenza: discovery and development of sialidase inhibitors. Nat Rev Drug Discov 2007;6(12):967-74
  • Matrosovich MN, Matrosovich TY, Gray T, et al. Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium. J Virol 2004;78(22):12665-7
  • Aoki FY, Macleod MD, Paggiaro P, et al. Early administration of oral oseltamivir increases the benefits of influenza treatment. J Antimicrob Chemother 2003;51(1):123-9
  • Gillissen A, Höffken G. Early therapy with the neuraminidase inhibitor oseltamivir maximizes its efficacy in influenza treatment. Med Microbiol Immunol 2002;191(3-4):165-8
  • Kandun IN, Tresnaningsih E, Purba WH, et al. Factors associated with case fatality of human H5N1 virus infections in Indonesia: a case series. Lancet 2008;372(9640):744-9
  • Kawai N, Ikematsu H, Iwaki N, et al. Factors influencing the effectiveness of oseltamivir and amantadine for the treatment of influenza: a multicenter study from Japan of the 2002-2003 influenza season. Clin Infect Dis 2005;40(9):1309-16
  • Leneva IA, Roberts N, Govorkova EA, et al. The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses. Antiviral Res 2000;48(2):101-15
  • Shijubo N, Yamada G, Takahashi M, et al. Experience with oseltamivir in the control of nursing home influenza A outbreak. Internal Med 2002;41(5):366-70
  • Moscona A. Oseltamivir resistance–disabling our influenza defenses. N Engl J Med 2005;353(25):2633-6
  • Zanamivir [package insert]. GlaxoSmithKline 2008 October
  • Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group. Lancet 1998;352(9144):1877-81
  • Hayden FG, Osterhaus AD, Treanor JJ, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group. N Engl J Med 1997;337(13):874-80
  • Barroso L, Treanor J, Gubareva L, Hayden FG. Efficacy and tolerability of the oral neuraminidase inhibitor peramivir in experimental human influenza: randomized, controlled trials for prophylaxis and treatment. Antiviral Ther 2005;10(8):901-10
  • Govorkova EA, Leneva IA, Goloubeva OG, et al. Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses. Antimicrob Agents Chemother 2001;45(10):2723-32
  • De Clercq E. Antiviral agents active against influenza A viruses. Nat Rev Drug Discov 2006;5(12):1015-25
  • Sugrue RJ, Tan BH, Yeo DSY, Sutejo R. Antiviral drugs for the control of pandemic influenza virus. Ann Acad Med Singapore 2008;37(6):518-24
  • Frost FJ, Petersen H, Tollestrup K, Skipper B. Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Chest 2007;131(4):1006-12
  • Available from: http://www.who.int/csr/disease/avian_influenza/guidelines/ClinicalManagement07.pdf
  • Howton JC. Probenecid with oseltamivir for human influenza A (H5N1) virus infection? N Engl J Med 2006;354(8):879-80
  • Hill G, Cihlar T, Oo C, et al. The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies. Drug Metab Dispos 2002;30(1):13-9
  • Holodniy M, Penzak SR, Straight TM, et al. Pharmacokinetics and tolerability of oseltamivir combined with probenecid. Antimicrob Agents Chemother 2008;52(9):3013-21
  • Rayner CR, Chanu P, Gieschke R, et al. Population pharmacokinetics of oseltamivir when coadministered with probenecid. J Clin Pharmacol 2008;48(8):935-47
  • Tamiflu [package insert]. Roche Laboratories Inc 2008 August
  • Lindegardh N, Davies GR, Tran TH, et al. Rapid degradation of oseltamivir phosphate in clinical samples by plasma esterases. Antimicrob Agents Chemother 2006;50(9):3197-9
  • Massarella JW, He GZ, Dorr A, et al. The pharmacokinetics and tolerability of the oral neuraminidase inhibitor oseltamivir (Ro 64-0796/GS4104) in healthy adult and elderly volunteers. J Clin Pharmacol 2000;40(8):836-43
  • Taylor WRJ, Thinh BN, Anh GT, et al. Oseltamivir is adequately absorbed following nasogastric administration to adult patients with severe H5N1 influenza. PloS One 2008;3(10):e3410
  • Available from: http://www.cdc.gov/flu/professionals/antivirals/side-effects.htm
  • Snell P, Oo C, Dorr A, Barrett J. Lack of pharmacokinetic interaction between the oral anti-influenza neuraminidase inhibitor prodrug oseltamivir and antacids. Br J Clin Pharmacol 2002;54(4):372-7
  • Snell P, Dave N, Wilson K, et al. Lack of effect of moderate hepatic impairment on the pharmacokinetics of oral oseltamivir and its metabolite oseltamivir carboxylate. Br J Clin Pharmacol 2005;59(5):598-601
  • Abe M, Smith J, Urae A, et al. Pharmacokinetics of oseltamivir in young and very elderly subjects. Ann Pharmacother 2006;40(10):1724-30
  • Schentag JJ, Hill G, Chu T, Rayner CR. Similarity in pharmacokinetics of oseltamivir and oseltamivir carboxylate in Japanese and Caucasian subjects. J Clin Pharmacol 2007;47(6):689-96
  • Li CY, Yu Q, Ye ZQ, et al. A nonsynonymous SNP in human cytosolic sialidase in a small Asian population results in reduced enzyme activity: potential link with severe adverse reactions to oseltamivir. Cell Res 2007;17(4):357-62
  • Worley KC, Roberts SW, Bawdon RE. The metabolism and transplacental transfer of oseltamivir in the ex vivo human model. Infect Dis Obstet Gynecol 2008;2008:927574
  • Wentges-van Holthe N, van Eijkeren M, van der Laan JW. Oseltamivir and breastfeeding. Int J Infect Dis 2008;12(4):451
  • Chang YM, Li WC, Huang CT, et al. Use of oseltamivir during an outbreak of influenza A in a long-term care facility in Taiwan. J Hosp Infect 2008;68(1):83-7
  • Hayden FG, Atmar RL, Schilling M, et al. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med 1999;341(18):1336-43
  • Hayden FG, Belshe R, Villanueva C, et al. Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis. J Infect Dis 2004;189(3):440-9
  • Peters PH, Gravenstein S, Norwood P, et al. Long-term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail older population. J Am Geriatr Soc 2001;49(8):1025-31
  • Welliver R, Monto AS, Carewicz O, et al. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA 2001;285(6):748-54
  • Halloran ME, Hayden FG, Yang Y, et al. Antiviral effects on influenza viral transmission and pathogenicity: observations from household-based trials. Am J Epidemiol 2007;165(2):212-21
  • Vu D, Peck AJ, Nichols WG, et al. Safety and tolerability of oseltamivir prophylaxis in hematopoietic stem cell transplant recipients: a retrospective case-control study. Clin Infect Dis 2007;45(2):187-93
  • Chik KW, Li CK, Chan PKS, et al. Oseltamivir prophylaxis during the influenza season in a paediatric cancer centre: prospective observational study. HongKong Med J 2004;10(2):103-6
  • Available from: http://www.cdc.gov/flu/professionals/antivirals/dosagetable.htm#table
  • Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA 2000;283(8):1016-24
  • Hayden FG, Jennings L, Robson R, et al. Oral oseltamivir in human experimental influenza B infection. Antiviral Ther 2000;5(3):205-13
  • Nicholson KG, Aoki FY, Osterhaus AD, et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet 2000;355(9218):1845-50
  • Hayden FG, Treanor JJ, Fritz RS, et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA 1999;282(13):1240-6
  • McGeer A, Green KA, Plevneshi A, et al. Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada. Clin Infect Dis 2007;45(12):1568-75
  • Bowles SK, Lee W, Simor AE, et al. Use of oseltamivir during influenza outbreaks in Ontario nursing homes, 1999-2000. J Am Geriatr Soc 2002;50(4):608-16
  • Bettis R, Iacuzio D, Jung T, et al. Impact of influenza treatment with oseltamivir on health, sleep and daily activities of otherwise healthy adults and adolescents. Clin Drug Invest 2006;26(6):329-40
  • Welton NJ, Cooper NJ, Ades AE, et al. Mixed treatment comparison with multiple outcomes reported inconsistently across trials: evaluation of antivirals for treatment of influenza A and B. Stat Med 2008;27(27):5620-39
  • Singh S, Barghoorn J, Bagdonas A, et al. Clinical benefits with oseltamivir in treating influenza in adult populations: results of a pooled and subgroup analysis. Clin Drug Invest 2003;23(9):561-9
  • Blumentals WA, Schulman KL. Impact of oseltamivir on the incidence of secondary complications of influenza in adolescent and adult patients: results from a retrospective population-based study. Curr Med Res Opin 2007;23(12):2961-70
  • Lee N, Chan PKS, Choi KW, et al. Factors associated with early hospital discharge of adult influenza patients. Antiviral Ther 2007;12(4):501-8
  • Ward P, Small I, Smith J, et al. Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. J Antimicrob Chemother 2005;55(Suppl 1):i5-21
  • Kaiser L, Wat C, Mills T, et al. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Inter Med 2003;163(14):1667-72
  • Kawai N, Ikematsu H, Iwaki N, et al. A comparison of the effectiveness of oseltamivir for the treatment of influenza A and influenza B: a Japanese multicenter study of the 2003-2004 and 2004-2005 influenza seasons. Clin Infect Dis 2006;43(4):439-44
  • Kawai N, Ikematsu H, Iwaki N, et al. A comparison of the effectiveness of zanamivir and oseltamivir for the treatment of influenza A and B. J Infect 2008;56(1):51-7
  • Kawai N, Ikematsu H, Iwaki N, et al. Longer virus shedding in influenza B than in influenza A among outpatients treated with oseltamivir. J Infect 2007;55(3):267-72
  • Sato M, Saito R, Sato I, et al. Effectiveness of oseltamivir treatment among children with influenza A or B virus infections during four successive winters in Niigata City, Japan. Tohoku J Exp Med 2008;214(2):113-20
  • Suzuki E, Ichihara K. The course of fever following influenza virus infection in children treated with oseltamivir. J Med Virol 2008;80(6):1065-71
  • Sugaya N, Tamura D, Yamazaki M, et al. Comparison of the clinical effectiveness of oseltamivir and zanamivir against influenza virus infection in children. Clin Infect Dis 2008;47(3):339-45
  • Wang H, Feng Z, Shu Y, et al. Probable limited person-to-person transmission of highly pathogenic avian influenza A (H5N1) virus in China. Lancet 2008;371(9622):1427-34
  • Yang Y, Halloran ME, Sugimoto JD, Longini IM. Detecting human-to-human transmission of avian influenza A (H5N1). Emerg Infect Dis 2007;13(9):1348-53
  • Schunemann HJ, Hill SR, Kakad M, et al. WHO Rapid Advice Guidelines for pharmacological management of sporadic human infection with avian influenza A (H5N1) virus. Lancet Infect Dis 2007;7(1):21-31
  • Available from: http://www.who.int/medicines/publications/WHO_PSM_PAR_2006.6.pdf
  • Yen HL, Monto AS, Webster RG, Govorkova EA. Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice. J Infect Dis 2005;192(4):665-72
  • Govorkova EA, Ilyushina NA, Boltz DA, et al. Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus. Antimicrob Agents Chemother 2007;51(4):1414-24
  • Available from: http://www.cidrap.umn.edu/cidrap/content/influenza/general/news/jun2207resist.html
  • McKimm-Breschkin JL, Selleck PW, Usman TB, Johnson MA. Reduced sensitivity of influenza A (H5N1) to oseltamivir. Emerg Infect Dis 2007;13(9):1354-7
  • Chotpitayasunondh T, Ungchusak K, Hanshaoworakul W, et al. Human disease from influenza A (H5N1), Thailand, 2004. Emerg Infect Dis 2005;11(2):201-9
  • Tran TH, Nguyen TL, Nguyen TD, et al. Avian influenza A (H5N1) in 10 patients in Vietnam. N Engl J Med 2004;350(12):1179-88
  • de Jong MD, Bach VC, Phan TQ, et al. Fatal avian influenza A (H5N1) in a child presenting with diarrhea followed by coma. N Engl J Med 2005;352(7):686-91
  • de Jong MD, Tran TT, Truong HK, et al. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med 2005;353(25):2667-72
  • Kandun IN, Wibisono H, Sedyaningsih ER, et al. Three Indonesian clusters of H5N1 virus infection in 2005. N Engl J Med 2006;355(21):2186-94
  • Oner AF, Bay A, Arslan S, et al. Avian influenza A (H5N1) infection in eastern Turkey in 2006. N Engl J Med 2006;355(21):2179-85
  • Boltz DA, Rehg JE, McClaren J, et al. Oseltamivir prophylactic regimens prevent H5N1 influenza morbidity and mortality in a ferret model. J Infect Dis 2008;197(9):1315-23
  • Monto AS, Rotthoff J, Teich E, et al. Detection and control of influenza outbreaks in well-vaccinated nursing home populations. Clin Infect Dis 2004;39(4):459-64
  • Toovey S. Influenza-associated central nervous system dysfunction: a literature review. Travel Med Infect Dis 2008;6(3):114-24
  • Toovey S, Rayner C, Prinssen E, et al. Assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: a comprehensive review. Drug Saf 2008;31(12):1097-114
  • Terada K, Kawai Y, Monju A, et al. Adolescent jump case in Japan associated with influenza but not oseltamivir. Pediatr Infect Dis J 2008;27(1):88-9
  • Blumentals WA, Song X. The safety of oseltamivir in patients with influenza: analysis of healthcare claims data from six influenza seasons. MedGenMed 2007;9(4):23
  • Okumura A, Kubota T, Kato T, Morishima T. Oseltamivir and delirious behavior in children with influenza. Pediatr Infect Dis J 2006;25(6):572
  • Available from: http://www.who.int/medicines/publications/newsletter/PN2008_2.pdf
  • Tamura D, Miura T, Kikuchi Y. Oseltamivir phosphate in infants under 1 year of age with influenza infection. Pediatr Int 2005;47(4):484
  • Okamoto S, Kamiya I, Kishida K, et al. Experience with oseltamivir for infants younger than 1 year old in Japan. Pediatr Infect Dis J 2005;24(6):575-6
  • Morimoto K, Nakakariya M, Shirasaka Y, et al. Oseltamivir (Tamiflu) efflux transport at the blood-brain barrier via P-glycoprotein. Drug Metab Dispos 2008;36(1):6-9
  • Aoki FY, Boivin G, Roberts N. Influenza virus susceptibility and resistance to oseltamivir. Antiviral Ther 2007;12(4 Pt B):603-16
  • Besselaar TG, Naidoo D, Buys A, et al. Widespread oseltamivir resistance in influenza A viruses (H1N1), South Africa. Emerg Infect Dis 2008;14(11):1809-10
  • Available from: http://www2a.cdc.gov/HAN/ArchiveSys/ViewMsgV.asp?AlertNum=00279
  • Available from: http://www.cdc.gov/flu/weekly/ - January 25 – 31, 2009
  • Available from: www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1232527287207
  • Available from: http://www.who.int/csr/disease/influenza/H1N1200801013.pdf
  • Available from: http://www.who.int/csr/disease/influenza/oseltamivir_faqs/en/
  • McSharry JJ, McDonough AC, Olson BA, Drusano GL. Phenotypic drug susceptibility assay for influenza virus neuraminidase inhibitors. Clin Diagn Lab Immunol 2004;11(1):21-8
  • McKimm-Breschkin JL. Resistance of influenza viruses to neuraminidase inhibitors–a review. Antiviral Res 2000;47(1):1-17
  • Yen HL, Herlocher LM, Hoffmann E, et al. Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility. Antimicrob Agents Chemother 2005;49(10):4075-84
  • Baz M, Abed Y, Boivin G. Characterization of drug-resistant recombinant influenza A/H1N1 viruses selected in vitro with peramivir and zanamivir. Antiviral Res 2007;74(2):159-62
  • Baz M, Abed Y, McDonald J, Boivin G. Characterization of multidrug-resistant influenza A/H3N2 viruses shed during 1 year by an immunocompromised child. Clin Infect Dis 2006;43(12):1555-61
  • van der Vries E, van den Berg B, Schutten M. Fatal oseltamivir-resistant influenza virus infection. N Engl J Med 2008;359(10):1074-6
  • Collins PJ, Haire LF, Lin YP, et al. Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants. Nature 2008;453(7199):1258-61
  • Zurcher T, Yates PJ, Daly J, et al. Mutations conferring zanamivir resistance in human influenza virus N2 neuraminidases compromise virus fitness and are not stably maintained in vitro. J Antimicrob Chemother 2006;58(4):723-32
  • Smith BJ, McKimm-Breshkin JL, McDonald M, et al. Structural studies of the resistance of influenza virus neuramindase to inhibitors. J Med Chem 2002;45(11):2207-12
  • Hurt AC, Selleck P, Komadina N, et al. Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes. Antiviral Res 2007;73(3):228-31
  • Le QM, Kiso M, Someya K, et al. Avian flu: isolation of drug-resistant H5N1 virus. Nature 2005;437(7062):1108
  • Bouvier NM, Lowen AC, Palese P. Oseltamivir-resistant influenza A viruses are transmitted efficiently among guinea pigs by direct contact but not by aerosol. J Virol 2008;82(20):10052-8
  • Herlocher ML, Truscon R, Elias S, et al. Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets. J Infect Dis 2004;190(9):1627-30
  • Moscona A, McKimm-Breschkin J. News about influenza B drug resistance that cannot be ignored. JAMA 2007;297(13):1492-3
  • Hatakeyama S, Sugaya N, Ito M, et al. Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors. JAMA 2007;297(13):1435-42
  • Gubareva LV, Matrosovich MN, Brenner MK, et al. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J Infect Dis 1998;178(5):1257-62
  • Gubareva LV. Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors. Virus Res 2004;103(1-2):199-203
  • Hurt AC, Iannello P, Jachno K, et al. Neuraminidase inhibitor-resistant and -sensitive influenza B viruses isolated from an untreated human patient. Antimicrob Agents Chemother 2006;50(5):1872-4
  • Govorkova EA, Fang H-B, Tan M, Webster RG. Neuraminidase inhibitor-rimantadine combinations exert additive and synergistic anti-influenza virus effects in MDCK cells. Antimicrob Agents Chemother 2004;48(12):4855-63
  • Ilyushina NA, Bovin NV, Webster RG, Govorkova EA. Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants. Antiviral Res 2006;70(3):121-31
  • Ilyushina NA, Hoffmann E, Salomon R, et al. Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice. Antiviral Ther 2007;12(3):363-70
  • Ilyushina NA, Hay A, Yilmaz N, et al. Oseltamivir-ribavirin combination therapy for highly pathogenic H5N1 influenza virus infection in mice. Antimicrob Agents Chemother 2008;52(11):3889-97
  • Galabov AS, Simeonova L, Gegova G. Rimantadine and oseltamivir demonstrate synergistic combination effect in an experimental infection with type A (H3N2) influenza virus in mice. Antiviral Chemistry Chemother 2006;17(5):251-8
  • Hayden FG, Schlepushkin AN, Pushkarskaya NL. Combined interferon-alpha 2, rimantadine hydrochloride, and ribavirin inhibition of influenza virus replication in vitro. Antimicrob Agents Chemother 1984;25(1):53-7
  • Hayden FG. Combinations of antiviral agents for treatment of influenza virus infections. J Antimicrob Chemother 1986;18(Suppl B):177-83
  • Hayden FG, Douglas RG, Simons R. Enhancement of activity against influenza viruses by combinations of antiviral agents. Antimicrob Agents Chemother 1980;18(4):536-41
  • Wilson SZ, Knight V, Wyde PR, et al. Amantadine and ribavirin aerosol treatment of influenza A and B infection in mice. Antimicrob Agents Chemother 1980;17(4):642-8
  • Nguyen J, Hoopes J, Liu C, et al. Modeling the Kinetics of Influenza A Resistance Under Drug Pressure. IDSA/ICAAC Conference 2008 2008;V-4142
  • Ison MG, Gnann JW, Nagy-Agren S, et al. Safety and efficacy of nebulized zanamivir in hospitalized patients with serious influenza. Antiviral Ther 2003;8(3):183-90
  • Morrison D, Roy S, Rayner C, et al. A randomized, crossover study to evaluate the pharmacokinetics of amantadine and oseltamivir administered alone and in combination. PloS One 2007;2(12):e1305
  • Available from: http://www.who.int/csr/disease/avian_influenza/guidelines/pharmamanagement/en/
  • Available from: www.clinicaltrials.gov
  • Kobayashi S, Kimura F, Kobayashi A, et al. Influenza virus reactivation after remission with oseltamivir treatment in a patient undergoing nonmyeloablative bone marrow transplantation. J Infect Chemother 2008;14(4):308-10
  • Carr J, Ives J, Kelly L, et al. Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo. Antiviral Res 2002;54(2):79-88
  • Gubareva LV, Robinson MJ, Bethell RC, Webster RG. Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en. J Virol 1997;71(5):3385-90
  • Yen HL, Hoffmann E, Taylor G, et al. Importance of neuraminidase active-site residues to the neuraminidase inhibitor resistance of influenza viruses. J Virol 2006;80(17):8787-95
  • Gubareva LV, Kaiser L, Matrosovich MN, et al. Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. J Infect Dis 2001;183(4):523-31
  • Gubareva LV, Webster RG, Hayden FG. Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants. Antimicrob Agents Chemother 2001;45(12):3403-8
  • Gubareva LV, Nedyalkova MS, Novikov DV, et al. A release-competent influenza A virus mutant lacking the coding capacity for the neuraminidase active site. J Gen Virol 2002;83(Pt 11):2683-92
  • Gubareva LV, Webster RG, Hayden FG. Detection of influenza virus resistance to neuraminidase inhibitors by an enzyme inhibition assay. Antiviral Res 2002;53(1):47-61
  • Abed Y, Baz M, Boivin G. Impact of neuraminidase mutations conferring influenza resistance to neuraminidase inhibitors in the N1 and N2 genetic backgrounds. Antiviral Ther 2006;11(8):971-6
  • Blick TJ, Tiong T, Sahasrabudhe A, et al. Generation and characterization of an influenza virus neuraminidase variant with decreased sensitivity to the neuraminidase-specific inhibitor 4-guanidino-Neu5Ac2en. Virology 1995;214(2):475-84
  • Goto H, Bethell RC, Kawaoka Y. Mutations affecting the sensitivity of the influenza virus neuraminidase to 4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid. Virology 1997;238(2):265-72
  • Barnett JM, Cadman A, Burrell FM, et al. In vitro selection and characterisation of influenza B/Beijing/1/87 isolates with altered susceptibility to zanamivir. Virology 1999;265(2):286-95
  • Staschke KA, Colacino JM, Baxter AJ, et al. Molecular basis for the resistance of influenza viruses to 4-guanidino-Neu5Ac2en. Virology 1995;214(2):642-6
  • Gubareva LV, Bethell R, Hart GJ, et al. Characterization of mutants of influenza A virus selected with the neuraminidase inhibitor 4-guanidino-Neu5Ac2en. J Virol 1996;70(3):1818-27
  • Escuret V, Frobert E, Bouscambert-Duchamp M, et al. Detection of human influenza A (H1N1) and B strains with reduced sensitivity to neuraminidase inhibitors. J Clin Virol 2008;41(1):25-8
  • Monto AS, McKimm-Breschkin JL, Macken C, et al. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob Agents Chemother 2006;50(7):2395-402
  • Ives JAL, Carr JA, Mendel DB, et al. The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antiviral Res 2002;55(2):307-17
  • Wang MZ, Tai CY, Mendel DB. Mechanism by which mutations at his274 alter sensitivity of influenza a virus n1 neuraminidase to oseltamivir carboxylate and zanamivir. Antimicrob Agents Chemother 2002;46(12):3809-16
  • Saad M, Boynton B, Earhart K, et al. Detection of Oseltamivir Reisistance mutation N294S in humans with Influenza A H5N1. Programs and abstracts of the Options for the Control of Influenza Conference 2007 June 17-23(228):Toronto
  • Abed Y, Nehme B, Baz M, Boivin G. Activity of the neuraminidase inhibitor A-315675 against oseltamivir-resistant influenza neuraminidases of N1 and N2 subtypes. Antiviral Res 2008;77(2):163-6

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.